Overview
Alnylam Pharmaceuticals, Inc. is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2002. It develops and commercializes RNA interference (RNAi) medicines, which use small interfering RNA to reduce production of proteins involved in disease. Its stated aim is to deliver medicines that transform patients’ lives through RNAi innovation.[1][2][3]
Alnylam’s medicines address conditions including transthyretin amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1. Its products include AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO; its broader portfolio of approved RNAi medicines also includes products developed with collaborators.[1] The company has a commercial presence in more than 70 markets through direct operations or distributors. In 2025, it reported approximately $3.71 billion in total revenue and employed approximately 2,500 full-time people at year-end.[4][5][6] [1][2][4][5][6][3]
Products & services
Alnylam’s marketed medicines use RNA interference to reduce production of proteins involved in specific diseases. AMVUTTRA (vutrisiran) is an under-the-skin treatment given every three months for adults with transthyretin amyloidosis with polyneuropathy or cardiomyopathy; ONPATTRO (patisiran) is an intravenous infusion given every three weeks for adults with hereditary transthyretin amyloidosis with polyneuropathy. Both reduce production of transthyretin in the liver.[7][8][9][10]
GIVLAARI (givosiran) is a monthly under-the-skin treatment for adults with acute hepatic porphyria that reduces production of the liver enzyme ALAS1. OXLUMO (lumasiran) treats primary hyperoxaluria type 1 in children and adults by reducing hepatic oxalate production; it is administered under the skin, with maintenance frequency determined by body weight.[11][12][13][14]
In 2025, AMVUTTRA accounted for approximately 77.5% of Alnylam’s $2.99 billion in net product revenue, followed by GIVLAARI at 10.3%, OXLUMO at 6.4% and ONPATTRO at 5.8%. Alnylam also developed Qfitlia (fitusiran), an under-the-skin preventive treatment for people aged 12 and older with hemophilia A or B, with or without factor inhibitors. Qfitlia is commercialized by Sanofi under a license from Alnylam rather than included in Alnylam’s product-sales breakdown.[15][16][17] [7][8][11][12][16][17][18][9][10][13][14][15]
Geographic presence
Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, and has an international headquarters in Zug, Switzerland. Its principal operating locations also include Maidenhead in the United Kingdom, Amsterdam in the Netherlands, and Tokyo, Japan. The company has a manufacturing facility in Norton, Massachusetts.[19][20]
In 2025, approximately $2.07 billion, or 69% of Alnylam’s net product revenue, came from the United States; $651 million, or 22%, from Europe; and $268 million, or 9%, from the rest of the world. These figures exclude collaboration and royalty revenue. At year-end 2025, approximately 1,945 of its 2,500 full-time employees were in the United States, with the remaining 555 outside the country.[15][21][6] [19][20][21][6][18][18][18][18][18][18][18][18][18][18][18][18][15]
Business segments
Alnylam Pharmaceuticals reports one operating and reportable segment: the discovery, development, manufacturing and commercialization of RNA interference (RNAi) therapeutics. It does not report separate segments by disease area, product or geography.[22]
Within that segment, Alnylam presents its medicines in two product groups. Transthyretin (TTR) products comprise AMVUTTRA and ONPATTRO, which address TTR amyloidosis; they accounted for approximately 83% of 2025 net product revenue. Rare-disease products comprise GIVLAARI, for acute hepatic porphyria, and OXLUMO, for primary hyperoxaluria type 1; together they accounted for approximately 17%. These percentages describe the product-revenue mix, not separate reportable segments or shares of total company revenue.[18][7][8][23][12] [22][18][18][18][7][8][23][12]
Company history
Alnylam Pharmaceuticals was founded in 2002 by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl and Phillip Zamore, with John Maraganore as its founding chief executive. The company went public in 2004. In 2013, it licensed a cholesterol-lowering RNA interference program to The Medicines Company, and in 2014 it expanded a development and commercialization alliance with Genzyme, a Sanofi company, focused on rare diseases.[3][24][25][26][27]
A defining milestone came in 2018, when the FDA approved Onpattro (patisiran) for a form of hereditary transthyretin-mediated amyloidosis, making it the first FDA-approved RNA interference medicine. Alnylam followed with FDA approvals for Givlaari (givosiran) in 2019, Oxlumo (lumasiran) in 2020 and Amvuttra (vutrisiran) in 2022. Yvonne Greenstreet succeeded Maraganore as chief executive in January 2022. In 2025, Amvuttra’s US approval was expanded to include adults with transthyretin amyloid cardiomyopathy.[28][29][30][31][24][32] [3][24][25][26][27][28][29][30][31][32]
Sources
- ALNYLAM PHARMACEUTICALS, INC. — Full financial report (2025 Y)
- investors.alnylam.com[3]
- www.alnylam.com[9]
- www.alnylam.com[10]
- www.alnylam.com[13]
- www.alnylam.com[14]
- www.sec.gov[15]
- investors.alnylam.com[24]
- investors.alnylam.com[25]
- www.sec.gov[26]
- www.sec.gov[27]
- www.alnylam.com[28]
- www.accessdata.fda.gov[29]
- www.accessdata.fda.gov[30]
- www.accessdata.fda.gov[31]
- www.accessdata.fda.gov[32]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore ALNYLAM PHARMACEUTICALS, INC. in Finbar ↗